Prognostic biomarkers in lung cancer patients in terms of long-term survival
Open Access
- 7 March 2021
- journal article
- Published by Turkish Journal of Internal Medicine in Turkish Journal of Internal Medicine
- Vol. 3 (Supplement), 20-22
- https://doi.org/10.46310/tjim.875437
Abstract
Introduction: We aimed to investigate the predictive effect of serum M30 and M65 antigens on long-term prognosis in patients with advanced stage lung cancer before and after the first dose of chemotherapy. Methods: Fourty eight patients with advanced stage lung cancer were included in the study. Demographic data and histopathological characteristics of the patients were recorded. Serum levels of M30 and M65 were studied in 48 patients before chemotherapy, and in 43 patients both before and 48 hours after chemotherapy. Long-term survival was evaluated using Kaplan-Meier curves. The effect of high or low M30, M65 levels and M30/M65 ratio on long-term survival was investigated. Results: The mean age of the patients at the time of diagnosis was 57.52 ± 9.38 years. Fourty six of the 48 patients were men. While M30 value before chemotherapy was 163.23 ± 112.30 U/l; It was measured as 249.74 ± 266.67 U/l 48 hours after chemotherapy (pKeywords
This publication has 12 references indexed in Scilit:
- Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinomaTumor Biology, 2014
- Clinical significance of serum M30 and M65 levels in melanomaMelanoma Research, 2013
- Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinomaTumor Biology, 2013
- Mechanisms involved in lung cancer development in COPDThe International Journal of Biochemistry & Cell Biology, 2011
- Is there any impact of plasma M30 and M65 levels on progression-free survival of patients with advanced gastric cancer?Cancer Chemotherapy and Pharmacology, 2010
- Serum M30 levels are associated with survival in advanced gastric carcinoma patientsInternational Immunopharmacology, 2010
- Circulating Cytokeratin 18 Fragment M65—A Potential Marker of Malignancy in Colorectal Cancer PatientsJournal of Gastrointestinal Surgery, 2009
- Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumorsInternational Immunopharmacology, 2009
- The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survivalLung Cancer, 2007
- Detection of epithelial cell death in the body by cytokeratin 18 measurementBiomedicine & Pharmacotherapy, 2005